We previously reported that some diffuse types of gastric cancer showed K-samII amplification, which encodes FGFR2 [11], and FGFR2 inhibitors were therapeutically promising for gastric carcinoma with FGFR2 amplification using several gastric cancer cell lines [12,13,14,15]. Here, FGFR2 is linked to gastric cancer.